The prevalence of Campylobacter and Salmonella spp. was determined from live bird to prepackaged carcass for 3 flocks from each of 6 types of California niche-market poultry. Commodities sampled included squab, quail, guinea fowl, duck, poussin (young chicken), and free-range broiler chickens. Campylobacter on-farm prevalence was lowest for squab, followed by guinea fowl, duck, quail, and free-range chickens. Poussin had the highest prevalence of Campylobacter. No Salmonella was isolated from guinea fowl or quail flocks. A few positive samples were observed in duck and squab, predominately of S. Typhimurium. Free-range and poussin chickens had the highest prevalence of Salmonella. Post-transport prevalence was not significantly higher than on-farm, except in free-range flocks, where a higher prevalence of positive chickens was found after 6 to 8 h holding before processing. In most cases, the prevalence of Campylobacter- and Salmonella-positive birds was lower on the final product than on-farm or during processing. Odds ratio analysis indicated that the risk of a positive final product carcass was not increased by the prevalence of a positive sample at an upstream point in the processing line, or by on-farm prevalence (i.e., none of the common sampling stations among the 6 commodities could be acknowledged as critical control points). This suggests that hazard analysis critical control point plans for Campylobacter and Salmonella control in the niche-market poultry commodities will need to be specifically determined for each species and each processing facility.

This study describes the prevalence of positive Campylobacter cultures from the skin, crop, and intestine of postscald broiler chicken carcasses at processing. Six to 12 carcasses from 22 flocks were sampled. Skin was cultured by direct plating of a cotton swab, whereas crop and intestine were cultured from tissue that was aseptically harvested and stomached in PBS before plating. Cultures were not enriched prior to plating. The methods used in this report are compared to those used by others. In this study, skin samples were 78% positive; crops were 48% positive, and intestines were 94% positive (n = 202). Based on our results, if the intestine was positive for Campylobacter, the odds of finding a positive crop culture was 8.6 times greater, and the odds of finding a positive skin culture was 35 times greater than if the intestinal culture was negative for Campylobacter. These data suggest that the intestine was the most likely organ of those tested to be positive in postscald broiler carcasses from positive flocks. Further, if only one organ can be sampled, intestinal samples are most likely to reflect the prevalence of Campylobacter in a flock.

This study was designed to compare virulence factors of cellulitis-derived Escherichia coli to colisepticemic E. coli in order to clarify whether E. coli associated with cellulitis comprise a unique subset of pathogenic E. coli. Isolates were tested for serotype, capsule, aerobactin production, colicin production, the presence of the iss gene, and serum resistance. Untypable isolates made up the greatest percentage of each group. Serotypes O2 and O78 were the most commonly identified among both groups of isolates. No statistical differences in the distribution of aerobactin or colicin production, capsule, or iss gene were observed between groups. Cluster analysis showed that 90% of the E. coli isolates had greater than 42% livability in serum-resistance tests. No separation of colisepticemic vs. cellulitis E. coli isolates was observed on the basis of SR. Colicin production by E. coli was highly correlated with serum resistance (P = 0.0029). These data suggest that cellulitis E. coli have virulence traits similar to those of colisepticemic E. coli.

Bovine mastitis is an economic burden for dairies worldwide. Mycoplasma species, and especially Mycoplasma bovis, are among the most important causative agents, and rapid, precise, and low-cost methods for Mycoplasma detection are urgently needed. For this purpose, loop-mediated isothermal amplification (LAMP) and quantitative PCR (qPCR) assays were developed and compared. The LAMP assay was designed and primer concentrations optimized to M. bovis oppD, encoding oligopeptide permease D. For qPCR, a Taqman assay (Applied Biosystems, Carlsbad, CA) targeting M. bovis gltX, encoding glutamate transfer RNA ligase, was optimized for primer concentration, annealing temperature, and DNA polymerase. Both assays were similarly sensitive, with a detection limit of approximately 10 4 to 10 5 M. bovis cells/mL. Both assays were also successful in confirming M. bovis identity in laboratory culture suspensions and in bovine milk. The LAMP and qPCR assays combined with the MoBio DNA extraction kit (MoBio Laboratories Inc., Carlsbad, CA) resulted in the correct detection of 13 out of 13 M. bovis isolates and 14 out of 16 M. bovis-positive milk samples collected from commercial dairies in California. When combined with the PrepMan Ultra reagent (Applied Biosystems), the qPCR assay resulted in confirming 21 out of 21 M. bovis-positive milk samples. Comparison of the assays to milk containing either Mycoplasma arginini, Mycoplasma bovigenitalium, Mycoplasma californicum, M. alkalescens, or Acholeplasma laidlawii or milk lacking any detectable Mycoplasma species or relatives resulted in 3 out of 17 (LAMP with MoBio), 1 out of 17 (qPCR with MoBio), and 2 out of 36 (qPCR with PrepMan Ultra) false positives. Overall, the qPCR assay was more robust than LAMP and could be used on DNA recovered from milk prepared with the PrepMan Ultra reagent, a method that does not include a DNA purification step. The use of this qPCR method enables M. bovis detection in bovine milk in 40 to 55 min, and therefore provides new opportunities to accelerate and simplify M. bovis detection in unpasteurized milk to reduce the incidence of M. bovis mastitis outbreaks.

Intramammary antibiotic (AB) and internal teat sealants (TS) infusion at dry-off have been used to prevent intramammary infections (IMI) in dairy cows during the dry period and reduce the risk of mastitis during the dry period and subsequent lactation. A randomized clinal trial was completed on eight California dairy herds to estimate the effects of different dry cow therapies (AB, TS, AB + TS or None) on clinical mastitis and culling. A total of 1273 cows were randomized to one of the four treatment groups over summer and winter seasons. For each enrolled cow, microbiological testing was done on quarter milk samples collected from the first detection of clinical mastitis within the first 150 days in milk (DIM) in the subsequent lactation. Statistical analysis was done using generalized linear mixed models. There were no significant differences in the odds of clinical mastitis or culling between cows treated with AB, TS, or AB + TS compared to the controls. Dry cow therapy with AB and/or TS had no statistically significant effect on clinical mastitis and cow culling during the first 150 DIM.